Every injury script flows through one screening point.
E-scripts are e-prescribed with MedPath set as pharmacy of choice and travel the ScriptNet / NCPDP SCRIPT path. MedPath captures and screens each one in near-real time, then routes the claimant into the right care pathway.
AI decision support — recommended for review, never autonomous.
An optional AI/ML model scores the signals on a claim and suggests a routing recommendation plus a risk flag. It assists human clinicians; it does not direct care.
Opioid Management — what happens inside that card.
The Opioid Management pathway is a spine of established utilization-management and clinical programs. MedPath intercepts, screens, and routes claims into them — early opioid prescribing is treated as a triage risk marker, not a causal driver. Pick an example claimant to light the path of programs it triggers, or click any program to see what it does.
Illustrative example claimants · sample routing logic
Illustrative concept for discussion. Programs shown are established utilization-management and clinical schemes; MedPath’s role is upstream interception and routing into them. Scenario routing is sample logic.
Treatment Pathway — routed to SUD care, then what?
This closes the loop: what happens once MedPath flags a high-risk or OUD-positive claimant. MedPath’s role is identification and routing, not treatment — the handoff is into SUD care, where structured, maintenance-oriented MOUD is one example of evidence-based downstream care, when indicated, delivered by licensed providers. Opioid exposure flags a claimant for assessment; it is a triage risk marker, not a diagnosis or a causal claim.
Illustrative concept for discussion. Depicts the handoff from MedPath interception into downstream SUD care — for example, a structured, medication-based treatment pathway when a licensed clinical assessment finds MOUD indicated. Treatment programs shown are established clinical schemes delivered by licensed providers; MedPath’s role is identification and routing, not treatment. Opioid exposure is treated as a triage risk marker, not a causal claim.